YD Bio Limited reported revenue of $846,501 for the six months ended June 30, 2026, up 315% from $204,007 a year earlier, and net income of $6.70 million versus a $1.92 million loss. Revenue growth was driven by higher sales of drugs and medical products, including a $327,060 Fetroja for Injection order from the company’s top client. The order represented 39% of first-half revenue, while the five largest products accounted for 57%. Gross profit rose to $268,230, but operating expenses increased 73% to $3.50 million, leaving a $3.23 million operating loss. A $9.85 million non-cash gain from the change in fair value of warrant liabilities generated most of the bottom-line profit; excluding that adjustment, the company recorded an unadjusted operational net loss of about $3.1 million. Cash and equivalents fell to $2.66 million from $6.01 million at Dec. 31, 2025. YD Bio said it is expanding its U.S. laboratory network, advancing a Canadian blood-based cancer-detection pilot, scaling exosome manufacturing and evaluating therapeutic and artificial-intelligence business combinations.